BriaCell Therapeutics Successfully Advances Towards Initiation of BriaVax™ Phase I/IIa Clinical Trial

October 8, 2015 Positive Release Testing Data From First Lot of Vaccine Submitted to FDA; Contract Negotiations Underway With Initial Clinical Site. BriaCell Therapeutics Corp (OTCQB: BCTXF) (TSX VENTURE: BCT) (“BriaCell”, the “Company”, or “BCT”) is pleased to announce that the Company has successfully advanced to the final stages of preparation for the upcoming Phase …

BriaCell Launches Development of Companion Diagnostic Product, BriaDx(TM)

Mon Sep 14, 2015 9:30am EDT BriaCell Launches Development of Companion Diagnostic Product, BriaDx(TM) Also Provides General Corporate Update Including Consolidation of Its Corporate Headquarters and Research Laboratories in San Francisco Bay Area; Attends NYC Biotechnology Conference and Posts Updated Investor Presentation VANCOUVER, BC–(Marketwired – September 14, 2015) – BriaCell Therapeutics Corp (OTCQB: ANCCF) (TSX …